Sponsored by Princeton CME and 
through an educational grant from 
Target Audience
This activity is designed for managed markets physicians, nurse practitioners, pharmacists, nurses, and case managers.
Learning Objectives
After completing this activity, participants should be able to:
- Identify epidemiology of ischemic stroke and its burden in payer and provider settings
- Compare current and emerging evidence of antiplatelet agents in secondary stroke prevention
- Select medication management strategies for secondary prevention of stroke based upon guidelines and evidence
Credit Eligibility
To be eligible for documentation of credit, participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.
Release Date: November 30, 2007
Expiration Date: November 30, 2008
Estimated time to complete: 1 hour
There is no fee associated with this activity.
Lecture Components
The presentation slides, post-test, and evaluation are available as a click through via the menu at the top of each page of this educational activity.
Physician Continuing Medical Education
Professional Resources in Management Education, Inc. (PRIME®) designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. AMA PRA Category 1 Credit is a trademark of the American Medical Association. PRIME® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Nurse Practitioner Continuing Education
PRIME® is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners: AANP Program ID#060815. This program has been approved for 1.0 contact hours of continuing education which includes .50 hour(s) of pharmacology.
Pharmacist Continuing Education
This curriculum has been approved for 1.0 contact hours by PRIME®. Professional Resources in Management Education, Inc. (PRIME®) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The universal program number for this activity is 255-000-07-024-H01.
Grievance Policy
For any concerns or comments regarding content please contact Lynn Goldenberg at l.goldenberg@primeinc.org
Nursing Continuing Education
PRIME® designates this educational activity for 1.0 contact hours by the Florida Board of Nursing and the California Board of Registered Nursing.
Case Management Continuing Education
The Commission for Case Manager Certification has approved this educational activity for 1.0 contact hours for certified case managers through PRIME®.
Grant Support
Sponsored by an educational grant from
Participating Faculty
Mark J. Alberts, MD
Professor of Neurology
Northwestern University, Feinberg School of Medicine
Director, Stroke Program
Northwestern Memorial Hospital
Chicago, Illinois
Independent Clinical Reviewer
John R. Sims II, MD
Assistant Professor, Harvard Medical School
Assistant in Neurology, Massachusetts General Hospital
Division of Stroke and Neurocritical Care
Charlestown, Massachusetts
PRIME® Disclosure Statement
PRIME® holds the standard that its continuing medical education programs be free of commercial bias. The faculty have been asked to disclose any relationship they have with companies producing pharmaceuticals, medical equipment, etc, that might be germane to their contribution(s) to this program or any relationship they may have with the commercial supporter of the program. These disclosures are not intended to suggest or condone bias but are elicited to provide participants with information that might be of potential importance in their evaluation of the program. The faculty have reported receiving something of value from a company whose product may be germane to the program content. Something of value refers to an equity position, vested interest, receipt of royalties, consultantship, funding by a research grant, honoraria, received for educational services, or any other relationship to a company that provides sufficient reason for disclosure. Please refer to the individual faculty biographies for individual disclosure information. The material presented here does not imply endorsement by PRIME®, the ACCME, the ACPE, the ANCC or other accreditation bodies through which PRIME sponsors educational programming. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Resolution of Conflict of Interest
PRIME® uses a comprehensive review process to resolve conflict of interest, including content validation, an internal quality assurance set of procedures, and an external peer review process.
The faculty has reported the following:
Dr. Alberts: Grant/research support—Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Novo Nordisk, and Sanofi; Consulting—Astra Zeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly & Co., Genenetch, KOS, Merck, Novo Nordisk, PDL BioPharma, Inc., Pfizer and Sanofi; Speaker’s bureau—Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Genentech, Novo Nordisk, PDL Biopharma, Inc. and Sanofi; Advisory board—Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly & Co., Genentech, KOS, Merck, Novo Nordisk, Pfizer and Sanofi.
Dr. Sims: Principal investigator—NIH (National Institutes of Health) with funds paid to Massachusetts General Hospital.
Planning Committee Lynn S. Goldenberg, RN, BSN, PRIME®; Randy Robbin and John Savage, Princeton CME; Rosemary Hodgson, Melissa Berman and William Kormos, Princeton Media Communications have disclosed they have no relevant financial relationships with any commercial interests.
PRIME® and Princeton CME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation.
The faculty has disclosed that no off-label/unapproved uses of drugs or devices will be discussed.
